19P * High reduction of circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin)
Manso, L., Moreno, F., Delgado, J. I., Echarri, M. J., Lopez, A., Izarzugaza, Y., Borrega, P., Martinez, N., Olier, C., Cortes-Funes, H.Volume:
26
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv115.07
Date:
May, 2015
Fichier:
PDF, 32 KB
2015
File converter
Plus de résultats de recherche
More benefits 
